Q1 2017 Specialty Pharmacy Pipeline Report

The increase in the number of specialty drugs and the cost of those drugs continues to be a major concern for all payers of health care claims.

Our Q1-2017 Specialty Pharmacy Pipeline Report provides an up-to-date summary of 20 drugs in the specialty pharmacy pipeline with expected approval dates through to the end of 2017.

The report includes:

  • Each drug’s generic name and brand name (if known)
  • The drug’s medical indication such as cancer, ALS (Lou Gehrig’s disease), Fabry disease, etc.
  • The drug’s route and mechanism of action
  • The expected cost of each drug, ranging up to $300,000 a year
  • Recommendations and comments from our pharmacy management Resources® partner, Excelsior Solutions

Download the new Q1 2017 Specialty Pharmacy Pipeline Report here for insight into how drugs in the pipeline will impact pharmacy costs and strategies to reduce these costs.

Post Comment

Your email address will not be published. Required fields are marked *